Cartesian Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: RNAC · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1453687
| Field | Detail |
|---|---|
| Company | Cartesian Therapeutics, Inc. (RNAC) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
Related Tickers: RNAC
TL;DR
Cartesian Therapeutics (RNAC) filed an 8-K for shareholder vote matters. Expect corporate action soon.
AI Summary
Cartesian Therapeutics, Inc. filed an 8-K on September 23, 2024, reporting on a submission of matters to a vote of security holders as of September 20, 2024. The company, formerly known as Selecta Biosciences Inc. until January 9, 2009, is incorporated in Delaware and headquartered in Gaithersburg, MD.
Why It Matters
This filing indicates that Cartesian Therapeutics is engaging in corporate actions requiring shareholder approval, which could impact the company's strategic direction and future operations.
Risk Assessment
Risk Level: medium — Filings related to shareholder votes can signal significant corporate events, such as mergers, acquisitions, or changes in governance, which carry inherent risks.
Key Numbers
- 001-37798 — SEC File Number (Identifies the company's filing with the SEC)
- 26-1622110 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- Cartesian Therapeutics, Inc. (company) — Registrant
- Selecta Biosciences Inc. (company) — Former company name
- 0001453687-24-000108 (filing_id) — Accession Number
- September 20, 2024 (date) — Date of earliest event reported
- September 23, 2024 (date) — Date of report
- 704 Quince Orchard Road, Gaithersburg, MD 20878 (address) — Principal executive offices
FAQ
What specific matters are being submitted for a vote of security holders?
The filing does not specify the exact matters to be voted on, only that a submission of matters to a vote of security holders is being reported.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 20, 2024.
What is the principal executive office address for Cartesian Therapeutics, Inc.?
The principal executive offices are located at 704 Quince Orchard Road, Gaithersburg, MD 20878.
What was Cartesian Therapeutics, Inc. formerly known as?
The company was formerly known as Selecta Biosciences Inc.
On what date was this 8-K form filed with the SEC?
This 8-K form was filed on September 23, 2024.
Filing Stats: 707 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-09-23 07:03:36
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind
Filing Documents
- rnac-20240920.htm (8-K) — 33KB
- 0001453687-24-000108.txt ( ) — 157KB
- rnac-20240920.xsd (EX-101.SCH) — 2KB
- rnac-20240920_lab.xml (EX-101.LAB) — 22KB
- rnac-20240920_pre.xml (EX-101.PRE) — 13KB
- rnac-20240920_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On September 20, 2024, Cartesian Therapeutics, Inc. (the "Company") held its previously announced Special Meeting of Stockholders (the "Special Meeting"). A total of 16,229,218 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), were present electronically or by proxy at the Special Meeting, representing approximately 75.90% of the Company's outstanding Common Stock as of the July 29, 2024 record date. The following are the voting results for the proposals considered and voted upon at the Special Meeting, both of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on August 16, 2024 (the "Proxy Statement"). Proposal 1: Approval of the issuance of shares of the Company's Common Stock upon conversion of the Company's Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series B Preferred Stock"). Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 12,514,261 150,060 1,650 — The above voting results for Proposal 1 do not include the 3,563,247 shares of Common Stock that were issued in the Company's July 2024 private placement transaction. Such shares were not entitled to vote on Proposal 1 for purposes of compliance with the applicable listing rules of The Nasdaq Stock Market LLC ("Nasdaq"). In order to comply with applicable Nasdaq rules, the Company instructed the inspector of elections to conduct a separate tabulation that subtracted 3,563,247 shares of Common Stock from the total number of shares of Common Stock that voted in favor of Proposal 1 to determine whether Proposal 1 was adopted in accordance with such rules. These 3,563,247 shares of Common Stock were eligible to vote on Proposal 1 for purposes of adopting Proposal 1 under Delaware law. Based on the votes set forth above, the stockholders of the Company approved Proposal 1. Proposal 2: Approval of the
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: September 23, 2024 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer